** ASX-listed shares of AVITA Medical AVH.AX rises as much as 3% to A$1.37, highest since August 29

** U.S.-based biotech firm says analysis of U.S. national burn registry data shows 36% shorter hospital stays in adults with deep second-degree burns treated with RECELL vs traditional skin grafting

** RECELL System is U.S. FDA-approved device used to treat thermal burns, trauma wounds

** AVH last up 1.1%, trimming YTD losses to 68.4%

(Reporting by Sherin Sunny in Bengaluru)

((Sherin.Sunny@thomsonreuters.com))